Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - April 23, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/23/17 - 5 Top NASDAQ Biotech Stocks: Neurocrine Biosciences Gained 32.68 Percent
Late last week Fiercebiotech reported on XBiotech likely getting rejected by the European Medicines Agency. Last week the company revealed its lead candidate is closer to obtaining FDA approval while saying it is tentatively targeting Q4 to launch and NDA. CytRx Corporation gained 40.82 percent last week to finish at $0.61 per share.
4/23/17 - Analyst Activity Cantor Fitzgerald Reiterates Buy on Aurinia Pharmaceuticals (NASDAQ:AUPH)
Analyst Ratings For Aurinia Pharmaceuticals (NASDAQ:AUPH) Today, Cantor Fitzgerald reiterated its Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a price target of $14.00. There are 7 buy ratings on the stock. The current consensus rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) is Buy (Score: 3.00) with a consensus target price of $11.00
4/23/17 - CHMP Recommends Approval Of Sandoz Biosimilar Rituximab And Etanercept In Europe
BASEL- Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use has recommended approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe for the same indications as their respective reference medicines. Subject to EC approval, Sandoz market leadership position extended as the only compa
4/23/17 - Data on Clinical Trials and Studies Described by Researchers at Fred Hutchinson Cancer Research Center [Midyear Commentary on Trends in Drug Delivery...
Data on Clinical Trials and Studies Described by Researchers at Fred Hutchinson Cancer Research Center. According to news reporting originating in Seattle, Washington, by NewsRx editors, the research stated, "Before the 2009 Biologics Price Competition and Innovation Act that enabled the U.S. Federal Drug Administration to create the 351 Biologic L
4/23/17 - Dr. Reddy's Lab launches Progesterone capsules in the U.S. market [India Infoline News Service]
Reddy s Laboratories Ltd., announced on April 21, 2017 that it has launched Progesterone Capsules, 100 mg and 200 mg in U.S. market Dr. Reddy s Laboratories Ltd. announced on April 21, 2017, that it has launched Progesterone Capsules, 100 mg and 200 mg, a therapeutic equivalent generic version of Prometrium* capsules in the United States mark
4/23/17 - Drug delivery co SteadyMed raises $30m [Globes, Tel Aviv, Israel]
April 23 Drug delivery company SteadyMed Ltd. has raised $30 million in a private placement led by Adage Capital Management, OrbiMed, Deerfield Management and Kingdon Capital Management. SteadyMed is a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet delivery
4/23/17 - FDA approves drugs more quickly than peer agency in Europe
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA New Haven, Conn. The U.S. Food and Drug Administration reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency, says a Yale researcher. This finding, which comes at a time when the FDA is under renewed pressure
4/23/17 - FDA clears heart disease trial at Boston Children's Hospital using mesoblast's cell therapy
By a News Reporter-Staff News Editor at Heart Disease Weekly BOSTON, NEW YORK, and MELBOURNE, Australia, Boston Children's Hospital, the pediatric teaching hospital of Harvard University, and Mesoblast Limited announced that the United States Food and Drug Administration has cleared the commencement of a 24- patient trial combining Mesoblast's.
4/23/17 - Medical Image Analysis Software Market by Software, Imaging Modalities, Applications, End Users and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc.
Medical Image Analysis Software Market by Software Type (Integrated, Standalone), Imaging Type (2D Imaging, 3D Imaging, 4D Imaging), Modality (CT, MRI, PET, SPECT, Ultrasound, Radiographic Imaging, Others), Application (Cardiology, Dental, Gynecology, Nephrology, Neurology, Oncology, Orthopedic, Others), End Users (Ambulatory Surgical Centers, Clin
4/23/17 - Researchers at Cardiac Surgery Division Report New Data on Post-Trial Research (Single versus double antiplatelet therapy in patients undergoing...
Researchers at Cardiac Surgery Division Report New Data on Post-Trial Research. By a News Reporter-Staff News Editor at Heart Disease Weekly Current study results on Clinical Trials and Studies- Post-Trial Research have been published. According to news reporting originating from Rome, Italy, by NewsRx correspondents, research stated, "Coronary..
4/23/17 - Sleep data startup EnsoData earns FDA clearance [The Wisconsin State Journal]
April 23 EnsoData, a Madison health IT company barely two years old, has won clearance from the U.S. Food and Drug Administration to sell its sleep-analysis software. "It's probably the biggest milestone for our company so far," said CEO and co-founder Chris Fernandez, 24. "We can legally sell it... all across the United States." EnsoSleep has b
4/23/17 - TAGRISSO osimertinib Receives US FDA Full Approval
By a News Reporter-Staff News Editor at Heart Disease Weekly AstraZeneca announced that the US Food and Drug Administration has granted full approval for TAGRISSO 80 mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA- ap
4/22/17 - AbbVie reports 99% cure rate for pan-genotypic Hep C therapy [Sport360]
G/P is a once-daily regimen that combines two distinct antiviral agents- the NS3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir- dosed once-daily as three oral tablets. However, treatment challenges remain related to the use of ribavirin, "commented Xavier Forns, head of hepatitis unit, Hospital Clinic de Barcelona, Spain.
4/22/17 - Acceleron Pharma, Cambridge, Mass., Dyax, Burlington, Mass., Assigned Patent for Polynucleotides Encoding Actriib Antibody
Acceleron Pharma, Cambridge, Massachusetts, and Dyax, Burlington, Massachusetts, have been assigned a patent developed by seven co-inventors for "polynucleotides encoding an actriib antibody." The co-inventors are Ravindra Kumar, Acton, Massachusetts, Asya Grinberg, Lexington, Massachusetts, Monique Davies, Harpswell, Maine, Diana Martik, Cambridge
4/22/17 - Achillion Pharmaceuticals, Inc. Position Cut by Metropolitan Life Insurance Co. NY [FARS News Agency]
Metropolitan Life Insurance Co. NY reduced its stake in Achillion Pharmaceuticals, Inc. by 6.5% during the fourth quarter, according to its most recent Form 13 F filing with the SEC. Metropolitan Life Insurance Co. NY owned approximately 0.06% of Achillion Pharmaceuticals worth $319,000 as of its most recent filing with the SEC. Whalerock Point Par
4/22/17 - Analyst Activity BTIG Research Initiates Coverage On Cascadian Therapeutics (NASDAQ:CASC) With a Buy
Analyst Ratings For Cascadian Therapeutics (NASDAQ:CASC) Today, BTIG Research initiated coverage on Cascadian Therapeutics (NASDAQ:CASC) with a Buy. There are 1 hold rating, 3 buy ratings on the stock. The current consensus rating on Cascadian Therapeutics (NASDAQ:CASC) is Buy (Score: 2.75) with a consensus target price of $6.00 per share, a potent
4/22/17 - Analyst Activity Cantor Fitzgerald Reiterates Buy on Aurinia Pharmaceuticals (NASDAQ:AUPH)
Analyst Ratings For Aurinia Pharmaceuticals (NASDAQ:AUPH) Today, Cantor Fitzgerald reiterated its Buy rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) with a price target of $14.00. There are 7 buy ratings on the stock. The current consensus rating on Aurinia Pharmaceuticals (NASDAQ:AUPH) is Buy (Score: 3.00) with a consensus target price of $11.00
4/22/17 - AP Top Health News at 2:46 a.m. EDT
Future of revamped health care bill remains dubious in House FDA approves 2nd near-copy of Remicade for immune disorders Indian public health group loses permit for foreign funds Lawmakers revisiting requiring those on Medicaid to work FDA further restricts pain medication use in kids Italy upholds vaccine requirements for preschoolers Germ in raw.
4/22/17 - AP Top Health News at 6:04 a.m. EDT
Future of revamped health care bill remains dubious in House FDA approves 2nd near-copy of Remicade for immune disorders Indian public health group loses permit for foreign funds Lawmakers revisiting requiring those on Medicaid to work FDA further restricts pain medication use in kids Italy upholds vaccine requirements for preschoolers Germ in raw.
4/22/17 - Arbutus Announces ARB-1467 Data Presentation at EASL
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, presented results of the first three cohorts of a Phase II study of its RNAi agent, ARB-1467, at the European Association for the Study of the Liver in Amsterdam, The Netherlands.. We are very pleased to present updated Phase II results for ARB-
4/22/17 - Astellas to Acquire Ogeda SA
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week- Astellas Pharma Inc. and Ogeda SA announced that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire Ogeda a privately owned drug discovery company. Under the agreement, Astellas has agreed to pay up to a total
4/22/17 - Atara Bio Announces Collaboration with Merck to Evaluate KEYTRUDA (pembrolizumab) in Combination with ATA129 in Nasopharyngeal Carcinoma (NPC) [T-break Tech (Middle East)]
-Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has entered into a clinical trial collaboration agreement with Merck, to evaluate Atara Bios allogeneic Epstein-Barr virus- specific cytotoxic T lymphocytes, or ATA129,
4/22/17 - Auris Medical Holding AG and Otonomy Seek FDA Approval for Drugs to Treat Ear Disorders
Auris Medical Holding AG and Otonomy Inc are set to release late-stage data from drug trials on treatments that could be used for tinnitus and Mnire's disease, according to an article in Reuters.
4/22/17 - BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317 [Syrian Arab News Agency]
-BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient was dosed in a pivotal clinical trial of BGB-A317, an investigational anti-PD-1 antibody, in Chinese patients with relapsed or refractory classical Hodgkin lymphoma.
4/22/17 - Bicycle Therapeutics Announces A Candidate Preclinical Milestone In Its Ophthalmology Alliance With ThromboGenics [Syrian Arab News Agency]
Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, today announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415